Abhishek A Mangaonkar1, Mrinal M Patnaik2. 1. Department of Hematology, Mayo Clinic, 200 1st street SW, Rochester, MN, 55905, USA. 2. Department of Hematology, Mayo Clinic, 200 1st street SW, Rochester, MN, 55905, USA. Patnaik.Mrinal@mayo.edu.
Abstract
PURPOSE OF REVIEW: Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20% 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group. RECENT FINDINGS: Elderly AML is a difficult entity to treat due to both disease and patient-related factors. Treatment of this group has a lot of inter-physician and inter-institutional variability. Several objective criteria to assess biological age, impact of co-morbidities, and fitness have been published, which could be utilized to make management decisions. For old and unfit AML patients, a variety of novel therapeutic agents are currently being investigated. Objective analysis of biological age should include assessment of fitness, frailty, and co-morbidities in elderly AML. Future areas of research include development of an objective risk-based approach and its validation in clinical trials, development of novel therapeutic agents, and improvement in supportive care measures.
PURPOSE OF REVIEW: Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20% 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group. RECENT FINDINGS: Elderly AML is a difficult entity to treat due to both disease and patient-related factors. Treatment of this group has a lot of inter-physician and inter-institutional variability. Several objective criteria to assess biological age, impact of co-morbidities, and fitness have been published, which could be utilized to make management decisions. For old and unfit AMLpatients, a variety of novel therapeutic agents are currently being investigated. Objective analysis of biological age should include assessment of fitness, frailty, and co-morbidities in elderly AML. Future areas of research include development of an objective risk-based approach and its validation in clinical trials, development of novel therapeutic agents, and improvement in supportive care measures.
Authors: Meir Wetzler; Krzysztof Mrózek; Jessica Kohlschmidt; Hervé Dombret; Hartmut Döhner; Sylvain Pilorge; Utz Krug; Andrew J Carroll; Richard A Larson; Guido Marcucci; Wolfgang Hiddemann; Thomas Büchner; Clara D Bloomfield Journal: Haematologica Date: 2013-10-04 Impact factor: 9.941
Authors: G Montalban-Bravo; X Huang; K Naqvi; E Jabbour; G Borthakur; C D DiNardo; N Pemmaraju; J Cortes; S Verstovsek; T Kadia; N Daver; W Wierda; Y Alvarado; M Konopleva; F Ravandi; Z Estrov; N Jain; A Alfonso; M Brandt; T Sneed; H C Chen; H Yang; C Bueso-Ramos; S Pierce; E Estey; Z Bohannan; H M Kantarjian; G Garcia-Manero Journal: Leukemia Date: 2017-03-24 Impact factor: 11.528
Authors: Todd A Fehniger; Geoffrey L Uy; Kathryn Trinkaus; Alissa D Nelson; Jeffery Demland; Camille N Abboud; Amanda F Cashen; Keith E Stockerl-Goldstein; Peter Westervelt; John F DiPersio; Ravi Vij Journal: Blood Date: 2010-11-04 Impact factor: 22.113
Authors: Arti Hurria; Constance T Cirrincione; Hyman B Muss; Alice B Kornblith; William Barry; Andrew S Artz; Linda Schmieder; Rafat Ansari; William P Tew; Douglas Weckstein; Jeffrey Kirshner; Kayo Togawa; Kurt Hansen; Vani Katheria; Richard Stone; Ilene Galinsky; John Postiglione; Harvey Jay Cohen Journal: J Clin Oncol Date: 2011-02-28 Impact factor: 44.544
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow Journal: Lancet Date: 2010-12-03 Impact factor: 79.321
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113